Avidity Biosciences Inc (NASDAQ: RNA) has experienced a rise in its stock price by 3.47 compared to its previous closing price of 28.56. However, the company has seen a fall of -0.34% in its stock price over the last five trading days. prnewswire.com reported 2025-02-28 that SAN DIEGO, Feb. 28, 2025 /PRNewswire/ — Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced it is joining the global community of patients, caregivers, families and healthcare providers to build broader awareness of rare diseases, including rare neuromuscular diseases, and the urgent need for more approved treatments for many of these conditions in support of Rare Disease Day®. “Rare Disease Day represents an important opportunity for all of us, including people living with rare diseases, their friends, family and caregivers, and advocacy organizations around the world, to spotlight the many challenges that rare diseases present in daily living,” said Sarah Boyce, President and Chief Executive Officer at Avidity.
Is It Worth Investing in Avidity Biosciences Inc (NASDAQ: RNA) Right Now?
The stock has a 36-month beta value of 1.03. Opinions on the stock are mixed, with 7 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for RNA is 111.07M, and at present, short sellers hold a 14.84% of that float. On March 06, 2025, the average trading volume of RNA was 1.36M shares.
RNA’s Market Performance
RNA’s stock has seen a -0.34% decrease for the week, with a -7.54% drop in the past month and a -31.33% fall in the past quarter. The volatility ratio for the week is 6.10%, and the volatility levels for the past 30 days are at 5.63% for Avidity Biosciences Inc. The simple moving average for the past 20 days is -6.77% for RNA’s stock, with a -23.52% simple moving average for the past 200 days.
Analysts’ Opinion of RNA
Many brokerage firms have already submitted their reports for RNA stocks, with H.C. Wainwright repeating the rating for RNA by listing it as a “Buy.” The predicted price for RNA in the upcoming period, according to H.C. Wainwright is $72 based on the research report published on December 20, 2024 of the previous year 2024.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see RNA reach a price target of $67. The rating they have provided for RNA stocks is “Outperform” according to the report published on November 26th, 2024.
Goldman gave a rating of “Buy” to RNA, setting the target price at $59 in the report published on September 24th of the previous year.
RNA Trading at -4.62% from the 50-Day Moving Average
After a stumble in the market that brought RNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -47.23% of loss for the given period.
Volatility was left at 5.63%, however, over the last 30 days, the volatility rate increased by 6.10%, as shares sank -11.37% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -3.75% lower at present.
During the last 5 trading sessions, RNA fell by -0.34%, which changed the moving average for the period of 200-days by +0.14% in comparison to the 20-day moving average, which settled at $31.70. In addition, Avidity Biosciences Inc saw 1.62% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RNA starting from Gallagher Kathleen P., who sale 5,875 shares at the price of $29.41 back on Mar 03 ’25. After this action, Gallagher Kathleen P. now owns 50,554 shares of Avidity Biosciences Inc, valued at $172,807 using the latest closing price.
Gallagher Kathleen P., the Chief Program Officer of Avidity Biosciences Inc, sale 5,875 shares at $32.16 during a trade that took place back on Feb 03 ’25, which means that Gallagher Kathleen P. is holding 50,554 shares at $188,918 based on the most recent closing price.
Stock Fundamentals for RNA
Current profitability levels for the company are sitting at:
- -34.77 for the present operating margin
- 0.88 for the gross margin
The net margin for Avidity Biosciences Inc stands at -29.58. The total capital return value is set at -0.26. Equity return is now at value -33.47, with -29.40 for asset returns.
Based on Avidity Biosciences Inc (RNA), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -44.24.
Currently, EBITDA for the company is -378.94 million with net debt to EBITDA at 0.57. When we switch over and look at the enterprise to sales, we see a ratio of 306.43. The receivables turnover for the company is 0.39for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 15.73.
Conclusion
To sum up, Avidity Biosciences Inc (RNA) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
